The thesis

STERIS plc provides infection prevention products and services with 7.3% YoY revenue growth. The company's conviction score is 8/100, indicating a dormant setup. High gross and net margins of 44.43% and 13.33% respectively suggest operational efficiency. Analyst consensus rating is BUY, despite low conviction.

Why now

The current macro context of increased sanctions and geopolitical tensions may drive demand for infection prevention products. STE's revenue growth and high margins make it an attractive play in the Healthcare sector.

What to watch

STERIS plc's next quarterly revenue growth report will indicate whether the current growth trajectory continues. Changes in analyst conviction scores will signal whether the BUY consensus is gaining or losing strength.

Key risks

Valuation risk is present with a P/E ratio of 27.2x. Execution risk is a concern given the low conviction score of 8/100. Macro risks related to geopolitical tensions and potential sanctions may impact supply chains and demand.

Theme exposure